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Intranuclear Neuronal Inclusions: Minireview
A Common Pathogenic Mechanism
for Glutamine-Repeat Neurodegenerative Diseases?
or could form between two molecules containing poly-
glutamine. Other molecules could then be recruited to
form a stable b-pleated sheet, which may aggregate
and precipitate within cells. Striking in vitro evidence
for the formation of aggregates containing polygluta-
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mine has recently been generated using a truncatedBaltimore, Maryland 21205
piece of the huntingtin protein encoded by exon 1 of
the HD gene (Scherzinger et al., 1997). Polarized light
microscopy revealed structural information consistent
Eight progressive neurodegenerative disorders, includ- with the possibility of b sheet formation.
ing Huntington's disease (HD) and several forms of Intranuclear Neuronal Inclusions
spinocerebellar ataxia (SCA; see Table 1), are currently Genetic manipulations have demonstrated that polyglu-
known to be caused by expanding CAG-triplet repeats tamine can lead to intranuclear protein aggregation and
coding for polyglutamine (Ross, 1995; Andrew et al., disease-like symptoms. Transgenic animals overex-
1997; Gusella et al., 1997). The genes causing these pressing the short exon 1 N-terminal fragment of the
degenerative disorders show no homology to each other huntingtin protein with a very long glutamine repeat de-
outside of the glutamine repeat, and most are genes of veloped a progressive neurological phenotype with
unknown function. In each of these diseases,an overlap- weight loss, involuntary movements, seizures, and early
ping but distinct set of cortical and subcortical regions death. The brains were smaller overall. Postmortem ex-
is affected. However, although the genes for the disor- amination of these animals revealed intranuclear inclu-
ders are expressed widely throughout the brain, and sions when labeled with antibodies to the N terminus
also in peripheral tissues, only certain populations of of huntingtin or to ubiquitin (Davies et al., 1997). The
neurons degenerate. The mechanism for this selective inclusions were most dense in the cortex and striatum,
neuronal death has remained puzzling. the areas affected in HD. The inclusions contained fibril-
Polyglutamine Pathogenesis lar and amorphous deposits of huntingtin, consistent
Genetic evidence, including the pattern of inheritance with protein aggregation.
of the disorders in patients and evidence from animal Similarly, mice transgenic for ataxin-1 (the protein
models, has suggested that these disorders are caused product of the SCA-1 gene) with expanded repeats un-
by a genetic ªgain-of-functionº mechanism. This con- der the control of a Purkinje cell±specific promotor show
cept is supported by the observation that the lengths small intranuclear deposits in Purkinje cells. In this
of the disease-causing repeats are similar for all of the model, the cells degenerate, as they do in patients with
genes and are longer than the corresponding normal SCA-1 (Skinner et al., 1997). Cell models also provide
alleles (Andrew et al., 1997; the one apparent exception, complementary results. Cells transiently transfected with
SCA-6, may involve a different pathogenic mechanism). either ataxin-1 or ataxin-3 show small intranuclear accu-
In all of the disorders, longer repeats yield earlier ages mulations of protein (Paulson et al., 1997; Skinner et al.,
of onset and more severe pathology. But how could 1997). Although these intranuclear inclusions are not
polyglutamine cause brain pathology? identical to those in the transgenic animals, these data
Perutz has suggested that long stretches of polyglu- indicate that the polyglutamine expansion can yield nu-
tamine might be able to form hydrogen bonds to other clear aggregation.
long stretches of polyglutamine in an antiparallel fashion Despite decades of study of pathological material
(Perutz et al., 1994). This so-called ªpolar zipperº could from human diseases, intranuclear inclusions had never
been noted as pathognomonic for these disorders.form as a hairpin within a single polyglutamine stretch
Table 1. Polyglutamine Disease Genes and Proteins
Molecular
Normal Expanded Weight Nuclear
Disease Gene Repeats* Repeats* Protein (kDa) Targetting
HD Huntingtin (IT15) 6-35 36-121 Huntingtin 348 2
DRPLA Atrophin-1 3-36 49-88 Atrophin-1 124 2
SCA-1 Ataxin-1 6-39 40-83 Ataxin-1 87 1
SCA-2 Ataxin-2 14-32 33-77 Ataxin-2 90 2
SCA-3 Ataxin-3 12-40 55-86 Ataxin-3 42 2
SCA-7 Ataxin-7 7-17 38-130 Ataxin-7 95 1
SBMA Androgen 9-36 38-62 AR 99 1
receptor (AR)
SCA-6** CACNL1A4 4-18 21-30** P/Q Ca21 channel (large) 2
* Data on repeat lengths in part from Andrew et al. (1997).
** The lengths of the expanded repeats are considerably shorter for SCA-6 than for the other genes, and the pathogenic mechanism may be
different.
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Figure 1. Tentative Model for Generation of Intranuclear Inclusions in Polyglutamine Diseases, Focusing on HD
(1) The normal protein, with its normal-length glutamine repeat.
(2) The expanded glutamine repeat undergoes a conformational change, presumably due to hairpin formation via a polar zipper. Interactions
with other proteins such as HAP1 and HIP1 are altered, possibly resulting in pathological events within the cytoplasm.
(3) The protein with the expanded glutamine repeat undergoes proteolytic cleavage, via caspase 3 or other enzymes. Dystrophic neurites
form in the cytoplasm (data not shown).
(4) The N-terminal fragment is translocated to the nucleus, where it may bind to the nuclear matrix (for ataxin-1, binding to LANP takes place
in the nuclear matrix), forming a nidus for additional molecules to associate via a b-pleated sheet.
(5) As additional huntingtin fragments aggregate, the proteins are modified by ubiquitinization.
(6) Proteins cannot be removed and form the intranuclear neuronal inclusions. Cytoplasmic aggregates can also form (data not shown), yielding
dystrophic neurites.
Thus, it is remarkable that this year intranuclear inclu- Mice with the CAG-repeat insertion developed a pro-
gressive late-onset behavioral phenotype, which in-sions have been identified in all four of the disorders in
which they have been sought (Becher et al., 1997; DiFig- cluded ataxia, seizures, and early death.
Neuropathological examination of the mice with thelia et al., 1997; Paulson et al., 1997; Skinner et al., 1997).
In each case, the inclusions have a similar appearanceÐ ectopic CAG repeats in HPRT revealed noclear neuronal
cell death, but intranuclear inclusions were evident whenwell-demarcated structures z2 mm across without a
surrounding membrane and distinct from the nucleolus. labeled with antibodies to the HPRT protein or ubiquitin.
Thus, CAG repeats translated into polyglutamine, evenSome neurons may have two or three inclusions, but
most neurons have only one. Furthermore, in HD, in in an ectopic protein without neurological function, can
produce a progressive neurological phenotype accom-which a sufficient number of cases have been studied,
there is a clear correlation between increasing CAG- panied by the formation of intranuclear inclusions. This
confirms that polyglutamine can directly yield aggrega-repeat length and increasing density of the inclusions
(Becher et al., 1997). In all of these disorders, the inclu- tion and supports the idea that intranuclear neuronal
inclusions are pathogenic. When taken together, thesesions can be labeled with antibodies to the disease
protein product itself or with antibodies to ubiquitin. results raise a number of questions.
What Is in the Nucleus and How DoesEctopic CAG Repeats
All of these results are consistent with the idea that It Get There?
HPRT is a relatively small protein of z48 kDa, includingexpanded stretches of polyglutamine can betoxic. How-
ever, they do not rule out the possibility that other com- the polyglutamine. Therefore, Ordway et al. (1997) pro-
pose that it enters the nucleus by diffusion, consistentponents of the disease gene products might be nec-
essary. The question remains: what would happen if with the cutoff of z50 kDa for passive exchange of
proteins between nucleus and cytoplasm. It is also pos-polyglutamine were expressed ectopically in thecontext
of a nonpathogenic protein? This experiment has now sible that passive diffusion accounts for the entry of
ataxin-3 into the nucleus, though with the expandedbeen performed by Detloff and colleagues (Ordway et
al., 1997). A long CAG repeat was inserted into the CAG repeat it runs on a denaturing gel as a protein of
nearly 70 kDa (Paulson et al., 1997). Presumably largermouse hypoxanthine-guanine phosphoribosyltransfer-
ase (HPRT) gene, which codes a metabolic enzyme. proteins would have to be translocated actively into the
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nucleus. Ataxin-1 has a nuclear import signal and is the GST appeared to inhibit formation of aggregates.
When the protein was cleaved from the GST, aggregatenormally enriched in the nucleusÐespecially in cerebel-
lar Purkinje cells, the cells most affected in SCA-1. formation was enhanced. The differences in sensitivity
to repeat number in the different diseases (Gusella etAtaxin-7 is present in nuclear fractions and also has a
nuclear localization signal. Similarly, the androgen re- al., 1997) could be due in part to a similar context effect.
Do Intranuclear Inclusions Kill Cells?ceptor of spinal and bulbar muscular atrophy (SBMA)
undergoes nuclear translocation on binding of andro- The intranuclear neuronal inclusions are now strong
candidates for a central role in the pathogenesis of allgen. However, the nuclear localization of the inclusions
in HD and dentato-rubral and pallido-luysian atrophy of the glutamine-repeat diseases. Consistent with this
is the distribution of the inclusions in brains of patients(DRPLA) are not accounted for, since both huntingtin
and atrophin 1 are large proteins without any nuclear with the various disorders. For instance, in HD the inclu-
sions are enriched in medium-sized neurons of the stria-localization signals. How might they enter the nucleus?
For huntingtin, there is evidence that proteolytic pro- tum and neurons of layers III, V, and VI of the cerebral
cortex, which are all selectively vulnerable in HD. Theycessing may be involved. Huntingtin can be cleaved by
caspase 3, one of the proteases involved in triggering are found less often in other brain regions and rarely, if
at all, in nonneuronal cells (Becher et al., 1997; DiFigliaapoptosis (Goldberg et al., 1996). It is possible that the
other glutamine-repeat proteins may also be cleaved by et al., 1997). Similarly, in DRPLA and in SCA-1 and
SCA-3, the inclusions appear to be enriched in the mostthis or related enzymes. This would fit with immunohisto-
chemical studies of the nuclear inclusions in HD, which vulnerable cells, although not as many cases have been
published as for HD (Becher et al., 1997; Paulson et al.,can identify inclusions with antibodies to the N terminus
of huntingtin but not with antibodies directed against 1997; Skinner et al., 1997).
In transgenic mice, the data are also consistent withinternal sequences (Becher et al., 1997; DiFiglia et al.,
1997). Furthermore, a z40 kDa huntingtin fragment rec- a role for the inclusions in thedevelopment of the pheno-
type. In the ataxin-1 transgenic mice, the inclusions areognized by the N-terminal antibody is enriched in nu-
clear fractions of brains from patients with HD (DiFiglia present before the onset of the phenotype, and the neu-
rons later degenerate. Similarly, in the HD exon-1 trans-et al., 1997). Thus, it is quite likely that, at least for
huntingtin, what accumulates is predominantly a small, genic mice, the inclusions are present before the onset
of the earliest behavioral symptoms (Davies et al., 1997).truncated fragment of the protein. A necessary patho-
genic event in HD therefore may be proteolytic cleavage In both the HD exon-1 model and in the HPRT model,
inclusions are present in great number, but neuronal cellby caspase, other proteolytic enzymes, or both.
However, even if the small portion of huntingtin can death cannot be demonstrated. It is possible that the
inclusions in this case cause neuronal dysfunction longenter the nucleus, why should it aggregate there? One
must also ask why other proteins that are normally cyto- before neuronal death. The mouse model of SCA-1
clearly indicates that neuronal dysfunction long pre-plasmic aggregate in the nucleus. Recent data may pro-
vide an answer for SCA-1. Yeast two-hybrid methods ceeds detectable neuronal death. Interestingly, occa-
sional HD patients are reported who have had clearwere used to identify a nuclear protein, the leucine-
rich acidic nuclear protein (LANP), which binds far more symptoms prior to death but have no qualitatively de-
tectable neuronal loss in the striatum.effectively to ataxin-1 with an expanded repeat than it
does to ataxin-1 with a normal repeat (Matilla et al., Nevertheless, the arguments linking intranuclear in-
clusions to cell death rest on correlation. As Ordway et1997). The two proteins colocalize in subdomains of the
nucleus termed nuclear bodies (Matilla et al., 1997). By al. (1997) point out, it is equally conceivable that the
inclusions are merely a marker for some other processcontrast, a number of other proteins present in other
subdomains of the nucleus did not colocalize with that is actually responsible for the neuronal cell death.
Conversely, the inclusions might be an attempt by theataxin-1 (Skinner et al., 1997). Thus, binding to ataxin-1
appears to alter the distribution of LANP within the nu- cell to defend against polyglutamine toxicity, and they
might actually exercise a protective role. These issuescleus and to make the two together bind tightly to the
nuclear matrix. It is possible that other nuclear binding could be addressed in cell-transfection experiments, by
designing constructs with nuclear localization or nuclearproteins, perhaps related to LANP, may aggregate with
truncated portions of other glutamine-repeat disease export signals strategically placed to increase or de-
crease the concentration of polyglutamine repeats inproteins. However, it is unclear if such protein interac-
tions could explain the preferential aggregation of the the nucleus.
Even if intranuclear inclusions were to have a caus-HPRT protein with its ectopically located glutamine re-
peat. At least for the interaction of ataxin-1 and LANP, ative role in neuronal cell death and dysfunction, the
mechanism remains unclear. The inclusions appear toother portions of the protein besides the glutamine re-
peat itself appear to be critically involved. How HPRT be relatively circumscribed and to exclude DNA (Davies
et al., 1997), suggesting that they don't physically disruptis recruited to nuclear inclusions, therefore, is uncertain.
In addition to possibly affecting where protein aggre- the chromatin in the nucleus. They may, however, have
more subtle effects on gene transcription. For instance,gates, in some way the ªcontextº provided by other
portions of the disease proteins appears to influence it is conceivable that they could alter transcription of
genes required for neuronal viability, perhaps includingthe ability of the polyglutamine to aggregate. In in vitro
aggregation experiments, the polyglutamine-containing glutamate receptors, mitochondrial proteins, or other
molecules previously implicated in neuronal vulnera-HD exon-1 construct was fused to glutathione S-trans-
ferase (GST; Scherzinger et al., 1997). In this complex, bility.
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Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H.,What Is the Significance of
Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L., and Bates,Cytoplasmic Aggregates?
G.P. (1997). Cell 90, 537±548.Dystrophic neurites that label for the N-terminal hunting-
DiFiglia, M.,Sapp, E.,Chase, K.O., Davies,S.W., Bates, G.P., Vonsat-tin antibody have been observed in HD (DiFiglia et al.,
tel, J.P., and Aronin, N. (1997). Science 277, 1990±1993.
1997). This raises the possibility that deposition of poly-
Goldberg, Y.P., Nicholson, D.W., Rasper, D.M., Kalchman, M.A.,
glutamine outside of the nucleus may also be important, Koide, H.B., Graham, R.K., Bromm, M., Kazemi-Esfarjani, P.,
at least in HD. Such deposition may take place in other Thornberry, N.A., Vaillancourt, J.P., and Hayden, M.R. (1996). Nat.
diseases. Paulson et al. (1997) observed ªdepositsº in Genet. 13, 442±449.
SCA-3. Similarly, a recent cell-transfection study (Ono- Gusella, J.F., Persichetti, F., and MacDonald, M.E. (1997). Mol. Med.
3, 238±246.dera et al., 1997) found that fusion proteins of polyglu-
tamine with green fluorescent protein (GFP) could form Matilla, A., Koshy, B.T., Cummings, C.J., Isobe, T., Orr, H.T., and
Zoghbi, H.Y. (1997). Nature 389, 974±978.cytoplasmic (and occasionally nuclear) aggregates,
Onodera, O., Burke, J.R., Miller, S.E., Hester, S., Tsuji, S., Roses,which disrupted the intermediate filament cytoskeleton.
A.D., and Strittmatter, W.J. (1997). Biochem. Biophys. Res. Com-It was not clear whether or not this was toxic to the cells.
mun. 238, 599±605.In addition, there could be a role for other interactions in
Ordway, J.M., Tallaksen-Greene, S., Gutekunst, C.-A., Bernstein,the cytoplasm. For instance, interactions of huntingtin
E.M., Cearley, J.A., Wiener, H.W., Dure, L.S., IV, Lindsey, R., Hersch,with other proteins may conceivably alter cell signaling
S.M., Jope, R.S., Albin, R.L., and Detloff, P.J. (1997). Cell 91,
or other events within the cytoplasm (Colomer et al., 753±763.
1997). Whether this has any role in the pathogenesis of Paulson, H.L., Perez, M.K., Trottier, Y., Trojanowski, J.Q., Subra-
the disease is still speculative. mony, S.H., Das, S.S., Vig, P., Mandel, J.-L., Fischbeck, K.H., and
What Is the Explanation for Pittman, R.N. (1997). Neuron 19, 333±344.
Differential Vulnerability? Perutz, M.F., Johnson, T., Suzuki, M., and Finch, J.T. (1994). Proc.
Natl. Acad. Sci. USA 91, 5355±5358.As noted above, the distribution of intranuclear inclu-
sions in brains from patients with several of the diseases Ross, C.A. (1995). Neuron 15, 493±496.
appears to match the distribution of pathology in these Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach,
B., Hasenbank, R., Bates, G.P., Davies, S.W., Lehrach, H., anddiseases, despite the fact that the mutant proteins are
Wanker, E.E. (1997). Cell 90, 549±558.widely expressed. How might this come about? One
Skinner, P.J., Koshy, B.T., Cummings, C.J., Klement, I.A., Helin, K.,possibility is the involvement of interacting proteins. The
Servadio, A., Zoghbi, H.Y., and Orr, H.T. (1997). Nature 389, 971±974.distribution of expression of LANP in normal brain corre-
sponds quite closely to the pattern of vulnerability in
SCA-1 (Matilla et al., 1997). This suggests a role for
LANP in specifying neuronal vulnerability by forming a
nidus for aggregation.
A second possibility is that protein cleavage itself is
a cell type±specific event. Experiments directed at this
issue will be necessary to resolve the factors governing
differential vulnerability of cells to protein aggregation.
Relation to Other Neurodegenerative Disorders
The unexpected discovery of inclusion bodies in the
polyglutamine disorders, and the clear demonstration
that polyglutamine-containing proteins can aggregate,
indicate that these polyglutamine disorders are more
similar to each other than was previously anticipated
and may be related to other neurodegenerative disor-
ders. As is described in the accompanying review (Lans-
bury, 1997 [this issue of Neuron]), protein aggregation
is a common mechanism in other late-onset neurode-
generative diseases, including Alzheimer's disease,
prion disease, and Parkinson's disease. Shared mecha-
nisms or shared biological modifiers may underlie sev-
eral of these diseases. Cross-fertilization among investi-
gators working on these various disorders is bound to
lead to rapid advances in our understanding of the
pathogenesis of these diseases.
Selected Reading
Andrew, S.E., Goldberg, Y.P., and Hayden, M.R. (1997). Hum. Mol.
Genet. 6, 2005±2010.
Becher, M.W., Kotzuk, J.A., Sharp, A.H., Davies, S.W., Bates, G.P.,
Price, D.L., and Ross, C.A. (1997). Neurobiol. Dis. 4, in press.
Colomer, V., Engelender, S., Sharp, A.H., Duan, K., Cooper, J.K.,
Lanahan, A., Lyford, G., Worley, P., and Ross, C.A. (1997). Hum.
Mol. Genet. 9, 1519±1525.
